Do 5α-Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications?

European Urology, Supplements

Volumn 5, Issue 12, 2006, Pages 752-757

  Lucia, M Scott ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

5 reductase inhibitor; Biopsy; Chemoprevention; Detection; Gleason grade; Prostate cancer

Indexed keywords

DUTASTERIDE; FINASTERIDE; GONADORELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER TISSUE; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; GLEASON SCORE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REDUCTION; REVIEW; RISK REDUCTION; STATISTICAL ANALYSIS;

EID: 33746676863     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.06.015     Document Type: Review

References (41)

1. Isaacs J.T. Antagonistic effect of androgens on prostatic cell death. Prostate 5 (1984) 545-557
2. Kyprianou K., English H.F., and Isaacs J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50 (1990) 3748-3753
3. Rittmaster R.S. 5 alpha-reductase inhibitors. J Androl 18 (1997) 582-587
4. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
5. Scardino P.T. The prevention off prostate cancer-the dilemma continues. N Engl J Med 349 (2003) 293-295
6. Marberger M., Adolfsson J., Borkowski A., et al. The clinical implications of the prostate cancer prevention trial. BJU Int 92 (2003) 667-671
7. Lucia MS, Darke A, Goodman P, et al. Pathological assessment of high grade tumors in the Prostate Cancer Prevention Trial (PCPT). Abstract presented at the American Urological Association Annual Meeting, San Antonio, TX, 21-26 May 2005.
8. Marks L.S., Partin A.W., Dorey F.J., et al. Long-term effects of finasteride on prostate tissue composition. Urology 53 (1999) 574-580
9. Civantos F., Watson R.B., Pinto J.E., Korman R.B., and Soloway M.S. Finasteride effect on prostatic hyperplasia and prostate cancer: a comparative clinico-pathologic study of radical prostatectomies. J Urol Pathol 6 (1997) 1-14
10. Montironi R., Valli M., and Fabris G. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. J Clin Pathol 49 (1996) 324-328
11. Pomante R., Santinelli A., Muzzonigro G., and Montironi R. Nodular hyperplasia of the prostate. Quantitative evaluation of secretory cell changes after treatment with finasteride. Anal Quant Cytol Histol 21 (1999) 63-69
12. Rittmaster R.S., Norman R.W., Thomas L.N., and Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 81 (1996) 814-819
13. Saez C., Gonzalez-Baena A.C., Japon M.A., et al. Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression. Prostate 37 (1998) 84-90
14. Thomas L.N., Wright A.S., Lazier C.B., Cohen P., and Rittmaster R.S. Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5. Prostate 42 (2000) 203-210
15. Glassman D.T., Chon J.K., Borkowski A., Jacobs S.C., and Kyprianou N. Combined effect of terazosin and finasteride on apoptosis, cell proliferation and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 46 (2001) 45-51
16. Hochberg D.A., Basillote J.B., Armenakas N.A., et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 167 (2002) 1731-1733
17. Pareek G., Shevchuk M., Armenakas N.A., et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 169 (2003) 20-23
18. Civantos F., Soloway M.S., and Pinto J.E. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 14 (1996) 22-31
19. Reuter V.E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49 (1997) 16-22
20. Yang X.J., Lecksell K., Short K., et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?. Urology 53 (1999) 696-700
21. Iczkowski K.A., Qiu J., Qian J., et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology 65 (2005) 76-82
22. Andriole G.L., Humphrey P., Ray P., et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 172 (2004) 915-919
23. Carver B.S., Kattan M.W., Scardino P.T., and Eastham J.A. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 95 (2005) 509-512
24. Rubin M.A., Allory Y., Molinie V., et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 66 (2005) 930-934
25. Klein E, Tangen C, Goodman P, Lippman S, Thompson I. Assessing benefit and risk in the prevention of prostate cancer: the Prostate Cancer Prevention Trial revisted. Abstract presented at the American Society of Clinical Oncology Prostate Cancer Symposium, Orlando, FL, 17-19 February 2005.
26. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
27. McConnell J.D., Bruskewitz R., Walsh P.C., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557-563
28. Debruyne F., Barkin J., van Erps P., et al. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488-495
29. Remzi M., Djavan B., Wammack R., et al. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy?. Urology 61 (2003) 161-166
30. Kulkarni G, Al-Azab R, Lockwood G, et al. Evidence for a biopsy-derived grade artifact among larger prostate glands: implications for the Prostate Cancer Prevention Trial. Abstract presented at the American Urological Association Annual Meeting, San Antonio, TX, 21-26 May 2005.
31. Guess H.A., Heyse J.F., Gormley G.J., Stoner E., and Oesterling J.E. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am 20 (1993) 627-636
32. Espana F., Martinez M., Royo M., et al. Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int 90 (2002) 672-677
33. Andriole G.L., and Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign hyperplasia. Eur Urol 44 (2003) 82-88
34. Andriole G.L., Guess H.A., Epstein J.I., et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology 52 (1998) 195-201
35. Andriole G.L., Marberger M., and Roehrborn C.G. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 175 (2006) 1657-1662
36. Guess H.A., Gormley G.J., Stoner E., and Oesterling J.E. The effect of finasteride on prostate specific antigen: review of available data. J Urol 155 (1996) 3-9
37. Oesterling J.E., Roy J., Agha A., et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Urology 51 (1998) 58-63
38. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
39. Thompson IM, Chi C, Goodman P, et al. Comparison of the operating characteristics of PSA for prostate cancer detection for finasteride and placebo in the Prostate Cancer Prevention Trial. Abstract presented at the American Urological Association Annual Meeting, Atlanta, GA, 20-25 May 2006.
40. Magklara A., Scorilas A., Stephan C., et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56 (2000) 527-532
41. Bartsch G., Fitzpatrick J., Schalken J., et al. Consensus statement: role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 93 (2004) 27-29